<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Second-line systemic therapy for advanced exocrine pancreatic cancer
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Second-line systemic therapy for advanced exocrine pancreatic cancer
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Second-line systemic therapy for advanced exocrine pancreatic cancer
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard M Goldberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth K Tanabe, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H596453308">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with locally advanced unresectable or metastatic exocrine pancreatic cancer, palliative systemic chemotherapy can improve disease-related symptoms and prolong survival. Options for second-line systemic therapy after progression on a first-line regimen will be reviewed here. Initial palliative systemic chemotherapy, specific methods for symptom palliation, and management of patients with metastatic well-differentiated neuroendocrine (islet cell) tumors are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2475.html" rel="external">
          "Initial systemic chemotherapy for metastatic exocrine pancreatic cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2505.html" rel="external">
          "Supportive care for locally advanced or metastatic exocrine pancreatic cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5659.html" rel="external">
          "Endoscopic ultrasound-guided celiac plexus interventions for pain related to pancreatic disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90664.html" rel="external">
          "Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H897402915">
         <span class="h1">
          SECOND-LINE THERAPY VERSUS SUPPORTIVE CARE ALONE AND PATIENT SELECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         A limited amount of data support a potential survival benefit for second-line chemotherapy compared with best supportive care alone. The only prospective data come from a trial in which 46 patients failing first-line
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         monotherapy were randomly assigned to best supportive care with or without OFF chemotherapy as follows [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          Oxaliplatin
         </a>
         85 mg/m
         <sup>
          2
         </sup>
         on days 8 and 22
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          Leucovorin
         </a>
         (LV) 200 mg/m
         <sup>
          2
         </sup>
         over 30 minutes followed by
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         (FU) 2000 mg/m
         <sup>
          2
         </sup>
         over 24 hours, with both drugs given on days 1, 8, 15, and 22
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Courses of chemotherapy repeated every six weeks
        </p>
        <p>
        </p>
        <p>
         The trial was stopped prematurely because of insufficient accrual. However, the treated group had a significantly longer median survival from the start of second-line treatment (4.8 versus 2.3 months) and longer median survival from the start of
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         (9 versus 7.9 months, p = 0.031).
        </p>
        <p>
         There are no prospective data addressing the survival benefit of second-line therapy after initial therapy with more-intensive first-line regimens (eg,
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         plus
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         and
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         and short-term infusional FU [FOLFIRINOX] or gemcitabine-based combinations). (See
         <a class="medical medical_review" href="/z/d/html/2475.html" rel="external">
          "Initial systemic chemotherapy for metastatic exocrine pancreatic cancer"
         </a>
         .)
        </p>
        <p>
         There is considerable heterogeneity in the survival of patients who receive second-line chemotherapy for advanced pancreatic cancer, and the best way to predict which patients will benefit is not established. Researchers have developed a nomogram to predict overall survival before administration of second-line chemotherapy, which may assist in clinical decision making [
         <a href="#rid2">
          2
         </a>
         ]. In an analysis derived from 462 consecutive patients with advanced pancreatic cancer treated at a single French institution over a 10-year period, age, smoking status, liver metastases, performance status (PS), pain, jaundice, ascites, and duration of first-line and type of second-line chemotherapy regimen were identified as independent prognostic factors for overall survival after second-line chemotherapy. These variables were utilized to develop a prognostic model, the validity of which was confirmed in an external validation cohort. Scores determined three groups with median overall survivals of 11.3, 3.6, and 1.4 months, respectively. By applying the score in the population that was eligible but did not receive second-line chemotherapy, the magnitude of expected chemotherapy benefit was higher in better prognostic groups. The model was then used to develop a
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.umqvc.org%2Fen%2Ftool%2Fproscap.html&amp;token=Yrx3yi7b83pql7MZushMAjWJ0xE34gWDcNZdK5HYE%2Fhul8dxFC9EorBRh%2BRevXxc7P0LssnkkUUqEpNnAPcFLA%3D%3D&amp;TOPIC_ID=127094" target="_blank">
          nomogram
         </a>
         allowing the estimation of median and individual overall survival probabilities following first-line chemotherapy.
        </p>
        <p>
         In our view, the decision to pursue second-line chemotherapy should be individualized and based on the patient's goals and preferences, and clinical prognostic characteristics such as those delineated in a prognostic
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.umqvc.org%2Fen%2Ftool%2Fproscap.html&amp;token=Yrx3yi7b83pql7MZushMAjWJ0xE34gWDcNZdK5HYE%2Fhul8dxFC9EorBRh%2BRevXxc7P0LssnkkUUqEpNnAPcFLA%3D%3D&amp;TOPIC_ID=127094" target="_blank">
          nomogram
         </a>
         . Factors influencing the choice of second-line therapy include the regimen used for first-line therapy, patient preference, and clinical characteristics, including PS  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 1
         </a>
         ) and comorbidity.
        </p>
        <p class="headingAnchor" id="H869878870">
         <span class="h1">
          GENERAL PRINCIPLES
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients being considered for second-line palliative systemic therapy, multiphasic computed tomography (CT) scan of the chest, abdomen, and pelvis should be performed to assess disease extent prior to initiating treatment [
         <a href="#rid3">
          3
         </a>
         ]. Other staging studies should be performed only as dictated by symptoms. Serum levels of the tumor marker carbohydrate antigen 19-9 (CA 19-9; also called cancer antigen 19-9), if elevated, may be used to follow disease status during chemotherapy. (See
         <a class="medical medical_review" href="/z/d/html/2501.html" rel="external">
          "Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer", section on 'Abdominal CT'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2475.html" rel="external">
          "Initial systemic chemotherapy for metastatic exocrine pancreatic cancer"
         </a>
         .)
        </p>
        <p>
         All patients with metastatic pancreatic cancer should be offered aggressive treatment for pain and other symptoms related to the cancer. Referral for a palliative care consultation should be considered early in the treatment course, especially for patients with a high symptom burden. Early initiation of palliative care services improves clinical and quality of care outcomes and may prolong survival. (See
         <a class="medical medical_review" href="/z/d/html/2505.html" rel="external">
          "Supportive care for locally advanced or metastatic exocrine pancreatic cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14240.html" rel="external">
          "Benefits, services, and models of subspecialty palliative care", section on 'Rationale for palliative care'
         </a>
         .)
        </p>
        <p>
         For patients with metastatic pancreatic cancer, genomic (ie, germline) testing (if not already known) and gene profiling of tumor tissue (ie, with next-generation sequencing) should be undertaken as quickly as possible after diagnosis because of the significant treatment implications both for first-line therapy and beyond [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2475.html" rel="external">
          "Initial systemic chemotherapy for metastatic exocrine pancreatic cancer", section on 'Germline and targeted tumor genomic testing'
         </a>
         and
         <a class="local">
          'Deficient mismatch repair or high tumor mutational burden'
         </a>
         below.)
        </p>
        <p>
         All patients should be offered information about clinical trials. Enrollment in clinical trials is preferred, if available. If protocol treatment is not available or participation is not feasible, chemotherapy is an option for patients with an adequate performance status (PS), controlled comorbidity, and a sufficient support system. Patients should understand that chemotherapy is palliative and not curative. Goals of care, patient preferences, treatment response, symptom burden, and psychosocial issues (including the patient's support system) should guide decisions for treatment [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/95552.html" rel="external">
          "Discussing goals of care"
         </a>
         .)
        </p>
        <p>
         If protocol treatment is not available or is declined, we base our treatment choice for second-line therapy on clinical characteristics, including PS and comorbidity, the presence or absence of germline or tumoral (somatic) alterations in genes associated with homologous recombination repair deficiency such as breast cancer-associated gene (
         <em>
          BRCA
         </em>
         ) and partner and localizer of
         <em>
          BRCA2
         </em>
         (
         <em>
          PALB2
         </em>
         ), histology, which regimen was used for first-line therapy, and patient preference, as outlined in the following sections.
        </p>
        <p class="headingAnchor" id="H453830169">
         <span class="h1">
          ADEQUATE PERFORMANCE STATUS AND COMORBIDITY
         </span>
        </p>
        <p class="headingAnchor" id="H3558108132">
         <span class="h2">
          Molecularly-targeted therapy
         </span>
        </p>
        <p class="headingAnchor" id="H3303785874">
         <span class="h3">
          BRCA or PALB2 mutation carriers and other homologous recombination repair deficiency alterations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pancreatic cancers that arise in the setting of an inherited mutation in breast cancer-associated (
         <em>
          BRCA1, BRCA2
         </em>
         ) or partner and localizer of BRCA2 (
         <em>
          PALB2
         </em>
         ) genes, and those with tumoral (somatic) mutations in these genes are associated with a defective DNA damage response, which increases sensitivity to DNA damaging agents such as platinum agents, and to drugs targeting the DNA damage response pathway, including poly(ADP-ribose) polymerase (PARP) inhibitors [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2475.html" rel="external">
          "Initial systemic chemotherapy for metastatic exocrine pancreatic cancer", section on 'Germline and targeted tumor genomic testing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83943.html" rel="external">
          "Familial risk factors for pancreatic cancer and screening of high-risk patients", section on 'Inherited cancer susceptibility syndromes'
         </a>
         .)
        </p>
        <p>
         Most patients who have germline or somatic mutations in
         <em>
          BRCA
         </em>
         or
         <em>
          PALB2
         </em>
         or other pathogenic or likely pathogenic variants in genes associated with homologous recombination repair deficiency (eg
         <em>
          , ATM
         </em>
         ,
         <em>
          BAP1
         </em>
         ,
         <em>
          BARD1
         </em>
         ,
         <em>
          BLM
         </em>
         ,
         <em>
          BRIP1
         </em>
         ,
         <em>
          CHEK2
         </em>
         ,
         <em>
          FAM175A
         </em>
         ,
         <em>
          FANCA
         </em>
         ,
         <em>
          FANCC
         </em>
         ,
         <em>
          NBN
         </em>
         ,
         <em>
          RAD50
         </em>
         ,
         <em>
          RAD51
         </em>
         ,
         <em>
          RAD51C
         </em>
         , and
         <em>
          RTEL1
         </em>
         ) will have received a platinum-containing regimen for first-line therapy (eg,
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         [LV] plus
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         and short-term infusional
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         [FU; FOLFOX], or FOLFIRINOX). For individuals with germline
         <em>
          BRCA
         </em>
         or
         <em>
          PALB2
         </em>
         mutations without disease progression after at least 16 weeks of platinum-based chemotherapy, maintenance therapy with the PARP inhibitor
         <a class="drug drug_general" data-topicid="98761" href="/z/d/drug information/98761.html" rel="external">
          olaparib
         </a>
         may have been initiated. (See
         <a class="medical medical_review" href="/z/d/html/2475.html" rel="external">
          "Initial systemic chemotherapy for metastatic exocrine pancreatic cancer"
         </a>
         .)
        </p>
        <p>
         At the time of disease progression, options include retreatment with the initial platinum-based regimen (if the patient was being maintained on a PARP inhibitor) or administration of a different platinum-containing regimen than what was administered first line (eg, FOLFOX for patients who previously received
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         , or vice versa). (See
         <a class="medical medical_review" href="/z/d/html/2475.html" rel="external">
          "Initial systemic chemotherapy for metastatic exocrine pancreatic cancer"
         </a>
         .)
        </p>
        <p>
         For patients who did not receive initial platinum-based chemotherapy, we suggest treatment with a platinum-based chemotherapy regimen for second-line therapy (eg,
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         , FOLFOX  (
         <a class="graphic graphic_table graphicRef50132" href="/z/d/graphic/50132.html" rel="external">
          table 2
         </a>
         ), FOLFIRINOX  (
         <a class="graphic graphic_table graphicRef79571" href="/z/d/graphic/79571.html" rel="external">
          table 3
         </a>
         ), or modified FOLFIRINOX  (
         <a class="graphic graphic_table graphicRef109546" href="/z/d/graphic/109546.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2475.html" rel="external">
          "Initial systemic chemotherapy for metastatic exocrine pancreatic cancer"
         </a>
         .)
        </p>
        <p>
         Another option, for patients who did not receive maintenance
         <a class="drug drug_general" data-topicid="98761" href="/z/d/drug information/98761.html" rel="external">
          olaparib
         </a>
         , is a PARP inhibitor. The available data on second-line PARP inhibitors after platinum-based chemotherapy are limited, but expanding [
         <a href="#rid5">
          5-7
         </a>
         ]. As an example, in a preliminary report of a Targeted Agent and Profiling Utilization Registry (TAPUR) study cohort of 30 patients with advanced pancreatic cancer, germline or somatic
         <em>
          BRCA1/2
         </em>
         inactivating mutations, and no standard treatment options (53 percent had received three or more prior lines of therapy) who received olaparib monotherapy (300 or 400 mg daily), there was one objective response and seven patients with stable disease (disease control rate 31 percent, objective response rate 4 percent) [
         <a href="#rid7">
          7
         </a>
         ]. The median progression-free survival (PFS) was 8.1 weeks, but 47 percent were still alive at one year.
        </p>
        <p>
         Whether outcomes are as favorable in patients who have pathogenic or likely pathogenic variants in genes other than BRCA that are associated with homologous recombination repair deficiency (eg,
         <em>
          ATM
         </em>
         ,
         <em>
          BAP1
         </em>
         ,
         <em>
          BARD1
         </em>
         ,
         <em>
          BLM
         </em>
         ,
         <em>
          BRIP1
         </em>
         ,
         <em>
          CHEK2
         </em>
         ,
         <em>
          FAM175A
         </em>
         ,
         <em>
          FANCA
         </em>
         ,
         <em>
          FANCC
         </em>
         ,
         <em>
          NBN
         </em>
         ,
         <em>
          PALB2
         </em>
         ,
         <em>
          RAD50
         </em>
         ,
         <em>
          RAD51
         </em>
         ,
         <em>
          RAD51C
         </em>
         , and
         <em>
          RTEL1
         </em>
         ) is unclear [
         <a href="#rid8">
          8
         </a>
         ]. Experience is limited and further study of this population is warranted.
        </p>
        <p>
         Notably, treatment with a PARP inhibitor in patients with advanced pancreatic cancer and a homologous recombination repair deficiency is not US Food and Drug Administration (FDA) approved and has not yet been considered a standard approach after failure of initial cytotoxic chemotherapy. Several trials examining this strategy are underway, and eligible patients should be encouraged to enroll. Outside of a protocol setting, in our view, for patients who do not undergo maintenance therapy with
         <a class="drug drug_general" data-topicid="98761" href="/z/d/drug information/98761.html" rel="external">
          olaparib
         </a>
         after first-line platinum-containing chemotherapy, the use of a PARP inhibitor is reasonable off label, especially in patients with a
         <em>
          BRCA1
         </em>
         or
         <em>
          2
         </em>
         pathogenic or likely pathogenic variant.
        </p>
        <p class="headingAnchor" id="H2786836568">
         <span class="h3">
          Deficient mismatch repair or high tumor mutational burden
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunotherapeutic approaches to cancer therapy are based on the premise that the immune system plays a key role in surveillance and eradication of malignancy and that tumors evolve ways to elude the immune system. (See
         <a class="medical medical_review" href="/z/d/html/99637.html" rel="external">
          "Principles of cancer immunotherapy"
         </a>
         .)
        </p>
        <p>
         Some cancers with deficient mismatch repair (dMMR; the biologic footprint of which is high levels of microsatellite instability [MSI-H]) are particularly sensitive to immune-based therapies. These tumors, which have high levels of tumor mutational burden (TMB), are thought to be more immunogenic and responsive to immune checkpoint inhibitor immunotherapy. Objective, in some instances complete, and durable responses to immune checkpoint inhibitors targeting the programmed cell death receptor 1 (PD-1; eg,
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         ) have been reported in a variety of patients with MSI-H cancers, including pancreatic cancers [
         <a href="#rid9">
          9-11
         </a>
         ]. As an example, in the phase II KEYNOTE-158 study, which enrolled 22 patients with pancreatic cancer [
         <a href="#rid11">
          11
         </a>
         ], there were four objective responses (18 percent), one of which was complete, and the median duration of response was 13.4 months.
        </p>
        <p>
         In the United States,
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         is now approved for treatment of a variety of advanced solid tumors, including pancreatic cancers, that are MSI-H or dMMR, that have progressed following prior treatment, and for which there are no satisfactory alternative treatment options, the first such approval of a tissue-agnostic anticancer treatment. Updated year 2020 guidelines from the American Society of Clinical Oncology (ASCO) endorse use of pembrolizumab as second-line therapy for individuals with MSI-H/dMMR tumors [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">
          "Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"
         </a>
         .)
        </p>
        <p>
         Unfortunately, ≤2 percent of advanced pancreatic cancers have dMMR [
         <a href="#rid10">
          10,12
         </a>
         ]. In other, unselected patients with advanced pancreatic cancer, the benefits of immunotherapy have not been established, and such treatment remains investigational [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         An important point is that MSI-H or dMMR may indicate the presence of Lynch syndrome, an inherited condition that predisposes to several cancers, including pancreatic cancer. All patients with an MSI-H/dMMR pancreatic cancer should undergo germline genetic assessment for Lynch syndrome, regardless of age or family history [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2605.html" rel="external">
          "Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Microsatellite instability testing'
         </a>
         .)
        </p>
        <p>
         While the vast majority of dMMR tumors have high TMB, not all TMB-high tumors have dMMR. There is increasing evidence of the benefit of immune checkpoint inhibitors in this population, and
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         is now also approved for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors that are tissue TMB high (≥10 mut/Mb) by an FDA-approved assay. Unfortunately, very few pancreatic cancers are proficient mismatch repair (pMMR)/TMB high, and it is not clear that they respond to immune checkpoint inhibitor immunotherapy [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">
          "Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Frequency of high TMB across tumor types'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">
          "Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Tumors with high mutational burden'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3307572258">
         <span class="h3">
          Next generation sequencing and targeted therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several ongoing trials (eg, the  [NCI-MATCH] and  trials) are using next-generation sequencing of multiple genes (gene panel tests) to identify molecular abnormalities in the tumors of patients with refractory cancers that may potentially match molecularly targeted therapies that are either in clinical trials or approved for treatment of other cancer types. Two such gene panel tests (the Memorial Sloan Kettering Cancer Center Integrated Mutation Profiling of Actionable Cancer Targets [MSK-IMPACT] and the FoundationOne CDx [F1CDx]) are FDA approved in the United States. (See
         <a class="medical medical_review" href="/z/d/html/17039.html" rel="external">
          "Next-generation DNA sequencing (NGS): Principles and clinical applications", section on 'Cancer screening and management'
         </a>
         .)
        </p>
        <p>
         In the setting of advanced pancreatic cancer, genomic (germline) or somatic tumor testing may identify potentially actionable alterations for which a clinical trial is available evaluating a targeted therapy that is approved for another type of cancer. It is estimated that approximately 25 percent of pancreatic cancers harbor potentially actionable molecular alterations, and that the adoption of precision medicine using molecularly guided treatments targeting oncogenic drivers and the DNA damage response and repair pathway can have a substantial impact on survival in patients with advanced pancreatic cancer [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         We prefer that these patients be enrolled in clinical trials, given that simply having a potentially targetable mutation does not guarantee that the patient will benefit from a therapy that presumably targets that mutation [
         <a href="#rid17">
          17
         </a>
         ]. However, targeted testing may also reveal other molecular abnormalities for which an approved treatment
         <strong>
          is
         </strong>
         available, as described in the sections below.
        </p>
        <p class="headingAnchor" id="H1257408891">
         <span class="h4">
          RET fusion-positive tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">
          Selpercatinib
         </a>
         is an option for advanced pancreatic cancer with a rearranged during transfection (
         <em>
          RET
         </em>
         ) gene fusion and disease progression on or following prior systemic treatment. Efficacy in 45 patients with a variety of solid tumors containing a
         <em>
          RET
         </em>
         fusion gene was addressed on the LIBRETTO-001 basket trial [
         <a href="#rid18">
          18
         </a>
         ]. In the entire cohort, the objective response rate was 44 percent, and median duration of response was 24.5 months; six of the 11 patients with advanced pancreatic cancer had a partial response (54 percent), and the median duration of response had not been reached with a median 14.9 months of follow-up. The most common grade ≥3 treatment-emergent adverse effects were hypertension and transaminase elevation.
        </p>
        <p>
         In September 2022, the US FDA granted a tissue-agnostic, accelerated approval to
         <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">
          selpercatinib
         </a>
         for adult patients with locally advanced or metastatic solid tumors with a
         <em>
          RET
         </em>
         gene fusion and disease progression on or following prior systemic treatment who have no satisfactory alternative treatment options. Unfortunately few patients with advanced pancreatic cancer (0.6 percent in one review of 160 patients [
         <a href="#rid19">
          19
         </a>
         ]) harbor a
         <em>
          RET
         </em>
         gene fusion.
        </p>
        <p class="headingAnchor" id="H5951319">
         <span class="h4">
          TRK fusion-positive cancers
         </span>
         <span class="headingEndMark">
          —
         </span>
         The tropomyosin receptor kinase (TRK) inhibitors
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         and
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         are approved broadly for cancers of any histology or origin that have a chromosomal rearrangement in one of the neurotrophic tyrosine receptor kinase (
         <em>
          NTRK
         </em>
         ) genes that are responsible for encoding the TRK proteins, resulting in a constitutively activated TRK fusion protein. Although one of these chromosomal rearrangements is rarely found in pancreatic ductal adenocarcinomas (detected in 0.34 and 0.56 percent of cases in two separate series [
         <a href="#rid20">
          20,21
         </a>
         ]), responses to TRK inhibition are reported in such cases [
         <a href="#rid22">
          22,23
         </a>
         ]. Updated year 2020 guidelines from ASCO endorse use of larotrectinib or entrectinib for second-line therapy for individuals with TRK fusion-positive pancreatic cancer [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/122713.html" rel="external">
          "TRK fusion-positive cancers and TRK inhibitor therapy", section on 'Treatment with TRK inhibitors'
         </a>
         .)
        </p>
        <p>
         Testing algorithms to identify TRK fusions are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/122713.html" rel="external">
          "TRK fusion-positive cancers and TRK inhibitor therapy", section on 'Testing algorithms'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2079785658">
         <span class="h4">
          RAS G12C-mutated tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with a
         <em>
          RAS
         </em>
         <em>
          G12C
         </em>
         mutation who have progressed on initial chemotherapy, we suggest
         <a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">
          sotorasib
         </a>
         rather than cytotoxic chemotherapy.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">
          Sotorasib
         </a>
         , a specific inhibitor of
         <em>
          RAS G12C
         </em>
         , is approved by the FDA for patients with
         <em>
          KRAS G12C
         </em>
         -mutated locally advanced or metastatic non-small cell lung cancer, who have received at least one prior systemic therapy. (See
         <a class="medical medical_review" href="/z/d/html/16538.html" rel="external">
          "Personalized, genotype-directed therapy for advanced non-small cell lung cancer", section on 'RAS mutations'
         </a>
         .)
        </p>
        <p>
         The
         <em>
          G12C
         </em>
         substitution is relatively uncommon in pancreatic ductal adenocarcinoma, comprising only 1 to 2 percent of all
         <em>
          RAS
         </em>
         mutations [
         <a href="#rid24">
          24,25
         </a>
         ]. The activity of
         <a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">
          sotorasib
         </a>
         in pancreatic cancer was initially noted in the CodeBreak100 phase I/II trial of 129 previously heavily treated patients; of the 12 who had pancreatic ductal adenocarcinoma, one had a confirmed objective response across several doses, and 8 others had stable disease (disease control rate 75 percent) [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         In a subsequent analysis of the CodeBreak 100 phase I/II trial,
         <a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">
          sotorasib
         </a>
         was evaluated in an expanded cohort of 38 patients with metastatic pancreatic ductal adenocarcinoma who had previously received systemic therapy [
         <a href="#rid27">
          27
         </a>
         ]. At median follow-up of 17 months, objective responses were confirmed in eight patients (21 percent), all of which were partial responses; the disease control rate was 84 percent. Median treatment duration was approximately 18 weeks. Median progression-free and overall survival were four and seven months, respectively
        </p>
        <p>
         The grade ≥3 toxicity rate for
         <a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">
          sotorasib
         </a>
         was 16 percent; the most common toxicities were diarrhea and fatigue (5 percent each). Other grade ≥3 toxicities included abdominal pain, increases in ALT or AST, pleural effusion, and pulmonary embolism. (See
         <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">
          "Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Sotorasib'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/128144.html" rel="external">
          "Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Molecularly targeted agents", section on 'Sotorasib'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4336.html" rel="external">
          "Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents", section on 'Sotorasib'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">
          Sotorasib
         </a>
         has several drug interactions and should typically not be coadministered with proton pump inhibitors, H2-receptor antagonists, strong cytochrome P450 3A4 (CYP3A4) inducers  (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 5
         </a>
         ), and certain CYP3A4 substrates and P-gp substrates.
        </p>
        <p class="headingAnchor" id="H2075384910">
         <span class="h2">
          Non-targeted therapy for adenocarcinomas
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are few randomized trials of second-line therapy for patients without potentially targetable molecular abnormalities who have failed initial gemcitabine-containing chemotherapy, and there is no universally accepted standard of care. There are even fewer data on second-line therapy for patients receiving a FU plus
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         regimen for first-line therapy. We prefer that eligible patients be enrolled on clinical trials testing new strategies. If protocol treatment is not available or is declined, we base our treatment choice on which regimen was used for first-line therapy and the patient's performance status (PS) and biliary function; our approach is consistent with updated Clinical Practice Guidelines from ASCO [
         <a href="#rid28">
          28
         </a>
         ] and consensus-based recommendations from the NCCN [
         <a href="#rid29">
          29
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who are refractory to or intolerant of first-line FOLFIRINOX who retain an Eastern Cooperative Oncology Group (ECOG) PS of 0 to 1  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 1
         </a>
         ), normal biliary function, and continued favorable comorbidity  (
         <a class="graphic graphic_table graphicRef118194" href="/z/d/graphic/118194.html" rel="external">
          table 6
         </a>
         ), we prefer
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">
          nabpaclitaxel
         </a>
         (
         <a class="graphic graphic_table graphicRef89668" href="/z/d/graphic/89668.html" rel="external">
          table 7
         </a>
         ). For others, we suggest gemcitabine monotherapy  (
         <a class="graphic graphic_table graphicRef60330" href="/z/d/graphic/60330.html" rel="external">
          table 8
         </a>
         ), gemcitabine plus
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         (
         <a class="graphic graphic_table graphicRef103038" href="/z/d/graphic/103038.html" rel="external">
          table 9
         </a>
         ), or a fluoropyrimidine alone. (See
         <a class="local">
          'After first-line FOLFIRINOX'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients initially treated with FOLFOX because of an elevated total bilirubin level who continue to have an elevated serum bilirubin level, second-line therapy should be undertaken only cautiously as
         <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">
          nanoliposomal irinotecan
         </a>
         ,
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         , and
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         have increased rates of toxicity at standard doses. (See
         <a class="local">
          'Patients with an elevated bilirubin level despite stenting'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients treated initially with a gemcitabine-containing regimen who retain a PS of 0 to 1 and a favorable comorbidity profile  (
         <a class="graphic graphic_table graphicRef118194" href="/z/d/graphic/118194.html" rel="external">
          table 6
         </a>
         ), combination chemotherapy using a regimen that contains FU and
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         , or FU and
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         is a reasonable approach.
         <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">
          Liposomal irinotecan
         </a>
         in combination with FU is also acceptable as long as liver function is adequate. For patients with an ECOG PS of 2 who have relatively favorable comorbidity  (
         <a class="graphic graphic_table graphicRef118194" href="/z/d/graphic/118194.html" rel="external">
          table 6
         </a>
         ), monotherapy may be appropriate. If single-agent therapy is chosen, options include FU plus LV,
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         alone, S-1 where available, or taxane monotherapy. (See
         <a class="local">
          'After first-line gemcitabine'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H557895682">
         <span class="h3">
          After first-line gemcitabine
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are few randomized trials examining the benefit of second-line therapy after failure of a gemcitabine-containing regimen. For patients who retain an ECOG PS of 0 or 1  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 1
         </a>
         ), have a relatively favorable comorbidity profile, a preference and support system for aggressive medical therapy, and access to chemotherapy port and infusion pump management services, combination chemotherapy using a regimen that contains FU plus
         <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">
          liposomal irinotecan
         </a>
         (as long as liver function is appropriate) or FU and unencapsulated
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         is a reasonable approach. We also consider that
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         combined with FU is also acceptable, although the phase III PANCREOX trial comparing modified FOLFOX6 with FU plus LV demonstrated a higher rate of grade 3 or 4 adverse effects and significantly reduced overall survival in the oxaliplatin group. FOLFIRINOX may be offered to patients with limited neuropathy and an excellent PS. (See
         <a class="local">
          'Oxaliplatin-based regimens'
         </a>
         below.)
        </p>
        <p>
         Options for single-agent therapy include FU/LV,
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         , and where available, S-1.
        </p>
        <p class="headingAnchor" id="H297732091">
         <span class="h4">
          Liposomal irinotecan
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">
          Liposomal irinotecan
         </a>
         (MM-398) is a liposomal encapsulated preparation that allows
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         to remain in circulation for a longer duration compared with standard irinotecan; this allows for higher drug uptake within tumor cells and conversion of irinotecan to its active form, SN38 [
         <a href="#rid30">
          30
         </a>
         ]. The efficacy of liposomal irinotecan in combination with FU and LV was assessed in the international phase III NAPOLI-1 trial, in which 417 patients with gemcitabine-refractory locally advanced or metastatic pancreatic cancer were randomly assigned to weekly administration of FU with LV for four of every six weeks (the control arm), liposomal irinotecan alone every three weeks, or liposomal irinotecan prior to FU and LV every two weeks [
         <a href="#rid31">
          31
         </a>
         ].
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         and a serotonin receptor antagonist could be administered in the combination arm per standard irinotecan protocols.
        </p>
        <p>
         Median overall survival, the primary endpoint, was longer with combination therapy (median 6.1 versus 4.2 months, hazard ratio [HR] 0.67, 95% CI 0.49-0.92), as was PFS (3.1 versus 1.5 months with control). At 12 weeks, 57 percent of patients treated with the combination were alive and progression free compared with only 26 percent of the control group. The objective response rate was 16 versus 1 percent. The most commonly reported grade 3 or worse adverse events with combination therapy were neutropenia (27 percent), fatigue (14 percent), diarrhea (13 percent), vomiting (11 percent), nausea (8 percent), asthenia (8 percent), and abdominal pain (7 percent).
         <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">
          Liposomal irinotecan
         </a>
         monotherapy did not demonstrate superior efficacy over the control arm, and it was associated with more severe toxicity than with combination therapy, suggesting that the drug should only be used in combination.
        </p>
        <p>
         Based on these results,
         <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">
          liposomal irinotecan
         </a>
         has been approved, in combination with FU and LV, for patients with metastatic pancreatic cancer following prior administration of a gemcitabine-based regimen. The recommended dose and schedule of liposomal irinotecan is 70 mg/m
         <sup>
          2
         </sup>
         administered by IV infusion over 90 minutes, prior to LV and FU, every two weeks. For patients who are known to be homozygous for the
         <em>
          UGT1A1
         </em>
         *28 or *6 allele (eg, those with Gilbert's syndrome), the recommended starting dose of liposomal irinotecan is lower, 50 mg/m
         <sup>
          2
         </sup>
         every two weeks. This subject is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/83810.html" rel="external">
          "Dosing of anticancer agents in adults", section on 'UGT1A1 polymorphisms and irinotecan'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1123802559">
         <span class="h4">
          Unencapsulated irinotecan
         </span>
         <span class="headingEndMark">
          —
         </span>
         Others have shown modest activity for
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         in combination with FOLFIRI [
         <a href="#rid32">
          32-34
         </a>
         ]. In two phase II studies totaling 90 patients with gemcitabine-refractory advanced pancreatic adenocarcinoma, the partial response rates were 8 and 14 percent, respectively, with disease control rates (objective response plus stable disease) of approximately 35 percent.
        </p>
        <p>
         Similar results have been demonstrated with second-line
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         plus S-1 [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H920754378">
         <span class="h4">
          Oxaliplatin-based regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several oxaliplatin-based regimens are active in patients who have failed single-agent
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         , including
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         plus FU and LV [
         <a href="#rid1">
          1,34,36-38
         </a>
         ], and oxaliplatin in combination with
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         [
         <a href="#rid38">
          38,39
         </a>
         ], S-1 [
         <a href="#rid40">
          40
         </a>
         ], gemcitabine [
         <a href="#rid41">
          41,42
         </a>
         ],
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         [
         <a href="#rid43">
          43,44
         </a>
         ], or
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regimens combining
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         plus FU and LV [
         <a href="#rid36">
          36,46,47
         </a>
         ] or oxaliplatin plus
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         [
         <a href="#rid36">
          36
         </a>
         ] may be superior to best supportive care alone or a fluoropyrimidine alone, although the data are disparate, as illustrated by the following observations:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         As noted above, the superiority of
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         (85 mg/m
         <sup>
          2
         </sup>
         on days 8 and 22) plus short-term infusional FU (2000 mg/m
         <sup>
          2
         </sup>
         over 24 hours) and LV (200 mg/m
         <sup>
          2
         </sup>
         over 30 minutes, both given on days 1, 8, 15, and 22; this regimen is referred to as OFF) compared with best supportive care alone was shown in a randomized phase III CONKO-003 trial [
         <a href="#rid1">
          1
         </a>
         ]. Each cycle was 42 days in length. The trial was stopped prematurely after the enrollment of only 46 patients because of low recruitment (best supportive care was not accepted by patients). Despite no confirmed responses better than stable disease, OFF was associated with a significantly longer median overall survival (4.8 versus 2.3 months). Patients receiving oxaliplatin had significantly more neurotoxicity (48 versus 10 percent), but it was mostly grade 1 or 2; otherwise, the regimen was well tolerated.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The contribution of
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         was addressed in a later trial in which the same schedule of FU and LV was tested with and without oxaliplatin in 168 patients with gemcitabine-refractory advanced pancreatic cancer; the majority (86 to 89 percent) had metastatic disease [
         <a href="#rid48">
          48
         </a>
         ]. The oxaliplatin group had significantly better overall survival (the primary endpoint; median 5.9 versus 3.3 months) and a significantly greater time to tumor progression (2.9 versus 2 months). There was no significant difference in the rates of grade 3 or 4 hematologic toxicities, although as expected, neurologic side effects were more prominent with OFF.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         On the other hand, a benefit for adding
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         to short-term infusional FU plus LV could not be shown in the phase III PANCREOX trial, in which 108 patients with advanced pancreatic cancer previously treated with
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         were randomly assigned to modified FOLFOX6 or short-term infusional FU/LV alone [
         <a href="#rid49">
          49
         </a>
         ]. PFS was similar, and median overall survival was actually inferior with FOLFOX (6.1 versus 9.9 months).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Despite these disparate findings, a 2018 focused update of the ASCO guidelines for therapy of metastatic pancreatic cancer continued to support an FU plus
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         regimen after failure of first-line
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">
          nabpaclitaxel
         </a>
         , although FU plus
         <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">
          nanoliposomal irinotecan
         </a>
         was preferred [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Combinations of
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         with
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         and S-1 are also active [
         <a href="#rid36">
          36,39,40
         </a>
         ]. In a phase II trial, 41 patients who failed one prior chemotherapy regimen received oxaliplatin (130 mg/m
         <sup>
          2
         </sup>
         every three weeks, decreased to 110 mg/m
         <sup>
          2
         </sup>
         for patients older than the age of 65 and those with a PS of 2  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 1
         </a>
         )) plus capecitabine (1000 mg/m
         <sup>
          2
         </sup>
         twice daily for 14 of every 21 days, decreased to 750 mg/m
         <sup>
          2
         </sup>
         for patients older than 65 and those with a PS of 2) [
         <a href="#rid39">
          39
         </a>
         ]. There was one partial response but a 22 percent clinical benefit rate; median PFS was 10 weeks. The 6- and 12-month survival rates were 44 and 21 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There are no prospective trials of FOLFIRINOX  (
         <a class="graphic graphic_table graphicRef79571" href="/z/d/graphic/79571.html" rel="external">
          table 3
         </a>
         ) in patients treated with first-line
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         . In a retrospective analysis of 27 patients treated with second-line FOLFIRINOX at a single institution over a six-year period, the objective response rate was 19 percent, 12 others had stable disease (44 percent), and the median time to tumor progression was 5.4 months [
         <a href="#rid50">
          50
         </a>
         ]. Grade 3 or 4 neutropenia developed in 56 percent of patients, but there was only one case of febrile neutropenia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In our view, it is reasonable to offer FOLFIRINOX as an option to patients with limited neuropathy and a good PS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Combinations of
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         with
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         are also active [
         <a href="#rid41">
          41,42
         </a>
         ]. As an example, in a study of 33 patients receiving second-line gemcitabine plus oxaliplatin, seven had a partial response, while 52 percent had clinical benefit [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 30 patients treated with
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         plus
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         , three had a partial response (two of whom subsequently underwent resection), and six had clinical benefit; 23 percent were still alive at one year [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3777877200">
         <span class="h4">
          Meta-analysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no randomized trials directly comparing an
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         versus an irinotecan-based regimen in this setting. A meta-analysis of five trials examining the effectiveness of adding oxaliplatin or various
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         formulations to a fluoropyrimidine after progression on a first-line gemcitabine-based regimen [
         <a href="#rid31">
          31,35,40,48,49
         </a>
         ] concluded that the combination of a fluoropyrimidine plus irinotecan significantly improved both PFS and overall survival (hazard ratio 0.7, 95% CI 0.55-0.89), while oxaliplatin-based combinations modestly improved PFS but not overall survival [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3798159041">
         <span class="h4">
          Other regimens
         </span>
        </p>
        <p class="headingAnchor" id="H1042415915">
         <span class="h5">
          Fluoropyrimidine monotherapy
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         S-1, an orally active fluoropyrimidine, is modestly active in gemcitabine-refractory disease [
         <a href="#rid52">
          52,53
         </a>
         ]. It is not available in the United States.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Modest utility for
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         (1000 mg/m
         <sup>
          2
         </sup>
         twice daily for 14 days of every 21-day cycle) plus
         <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">
          erlotinib
         </a>
         (150 mg once daily) was suggested in a phase II trial of 32 patients with gemcitabine-refractory advanced pancreatic cancer [
         <a href="#rid54">
          54
         </a>
         ]. Although only three patients (10 percent) achieved a radiologic response, five others had a ≥50 percent decrease in carbohydrate antigen 19-9 (CA 19-9; also called cancer antigen 19-9) level, and median survival was 6.5 months. Grade 3 or 4 toxicities included diarrhea (17 percent), rash (13 percent), hand-foot syndrome (13 percent), and stomatitis (10 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2594420539">
         <span class="h5">
          Raltitrexed combinations
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10087" href="/z/d/drug information/10087.html" rel="external">
          Raltitrexed
         </a>
         (Tomudex), a folate analog, is a pure thymidylate synthase inhibitor that is available in Canada and elsewhere, but not in the United States. Activity for raltitrexed in combination with
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         was shown in a randomized phase II trial that compared 21-day cycles of raltitrexed (3 mg/m
         <sup>
          2
         </sup>
         on day 1) with 21-day cycles of irinotecan (200 mg/m
         <sup>
          2
         </sup>
         on day 1) plus raltitrexed (3 mg/m
         <sup>
          2
         </sup>
         day 2) in 38 patients who failed
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         [
         <a href="#rid55">
          55
         </a>
         ]. Combined therapy was superior in terms of objective response rate (16 versus 0 percent), clinical benefit rate (29 versus 8 percent), PFS (4 versus 2.5 months), and overall survival (6.5 versus 4.3 months).
        </p>
        <p>
         Comparable results were also seen in a single-arm trial of 21-day cycles of
         <a class="drug drug_general" data-topicid="10087" href="/z/d/drug information/10087.html" rel="external">
          raltitrexed
         </a>
         (3 mg/m
         <sup>
          2
         </sup>
         on day 1) plus
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         (130 mg/m
         <sup>
          2
         </sup>
         on day 1) after failure of first-line
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         [
         <a href="#rid56">
          56
         </a>
         ]. Ten of 41 patients (24 percent) had a partial response, and the median survival was 5.2 months.
        </p>
        <p class="headingAnchor" id="H3131420002">
         <span class="h5">
          Taxane monotherapy
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Second-line weekly
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         was studied in 30 patients who failed
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         [
         <a href="#rid57">
          57
         </a>
         ]. The objective response rate was 10 percent, and the overall disease control rate was 47 percent (14 of 30 patients); median survival from the start of paclitaxel was 6.7 months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">
          Nabpaclitaxel
         </a>
         (Abraxane) is also modestly active as a second-line agent after first-line
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         monotherapy. In a phase II trial in which 19 patients with gemcitabine-refractory advanced pancreatic cancer received single-agent nabpaclitaxel (100 mg/m
         <sup>
          2
         </sup>
         on days 1, 8, and 15 of each 28-day cycle), one had a partial response, and six had stable disease as the best response [
         <a href="#rid58">
          58
         </a>
         ]. The estimated median overall survival was 7.3 months.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3119235810">
         <span class="h3">
          After first-line FOLFIRINOX
         </span>
         <span class="headingEndMark">
          —
         </span>
         For individuals previously treated with first-line FOLFIRINOX who retain an ECOG PS of 0 to 1  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 1
         </a>
         ), normal biliary function, continued favorable comorbidity  (
         <a class="graphic graphic_table graphicRef118194" href="/z/d/graphic/118194.html" rel="external">
          table 6
         </a>
         ), and a preference and support system for aggressive medical therapy we suggest
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">
          nabpaclitaxel
         </a>
         (
         <a class="graphic graphic_table graphicRef89668" href="/z/d/graphic/89668.html" rel="external">
          table 7
         </a>
         ). For others, gemcitabine monotherapy  (
         <a class="graphic graphic_table graphicRef60330" href="/z/d/graphic/60330.html" rel="external">
          table 8
         </a>
         ), gemcitabine plus
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         (
         <a class="graphic graphic_table graphicRef103038" href="/z/d/graphic/103038.html" rel="external">
          table 9
         </a>
         ), or a fluoropyrimidine alone are all reasonable options.
        </p>
        <p>
         There are few data on second-line chemotherapy in patients failing first-line LV plus short-term infusional FU plus
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         and
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         (FOLFIRINOX) and no randomized trials. (See
         <a class="medical medical_review" href="/z/d/html/2475.html" rel="external">
          "Initial systemic chemotherapy for metastatic exocrine pancreatic cancer", section on 'FOLFOX and FOLFIRINOX'
         </a>
         .)
        </p>
        <p>
         Potential options in this setting include
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">
          nabpaclitaxel
         </a>
         , gemcitabine monotherapy, or a single-agent taxane. Updated year 2020 guidelines for treatment of metastatic pancreatic cancer from ASCO endorse gemcitabine plus nabpaclitaxel for those patients who retain an ECOG PS 0 to 1, have a relatively favorable comorbidity profile, a preference and support system for aggressive medical therapy, and access to chemotherapy port and infusion pump management services [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The efficacy and tolerability of
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">
          nabpaclitaxel
         </a>
         (
         <a class="graphic graphic_table graphicRef89668" href="/z/d/graphic/89668.html" rel="external">
          table 7
         </a>
         ) in this setting has been addressed in the following reports:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a prospective multicenter cohort study of 57 consecutive patients progressing while receiving FOLFIRINOX, the objective response rate was 18 percent, the overall disease control rate was 58 percent, median overall survival was 8.8 months, and the median PFS was 5.1 months [
         <a href="#rid59">
          59
         </a>
         ]. Grade 3 or 4 toxicities were experienced by 40 percent of treated patients and included neutropenia (13 percent), neurotoxicity (13 percent), asthenia (9 percent), and thrombocytopenia (7 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similar results were reported in a small multicenter phase II trial of 30 patients receiving second-line
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         /
         <a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">
          nabpaclitaxel
         </a>
         after failure of first-line FOLFIRINOX [
         <a href="#rid60">
          60
         </a>
         ]. The objective response rate was 13 percent, disease control rate was 47 percent, and median overall survival and PFS were 7.6 and 3.8 months, respectively. Grade 3 or 4 adverse events included neutropenia (50 percent), febrile neutropenia (6.7 percent), thrombocytopenia (20 percent), anemia (27 percent), peripheral sensory neuropathy and anorexia (13 percent each).
        </p>
        <p>
        </p>
        <p>
         Whether these results are better than could be expected with
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         monotherapy is not clear, given that there are no randomized trials, and the only data on gemcitabine alone are from uncontrolled series (response rates average 8 to 11 percent, disease control rate 26 to 40 percent, median overall survival 3.6 to 5.7 months, and median PFS values of 1.5 to 2.5 months [
         <a href="#rid61">
          61-65
         </a>
         ]).
        </p>
        <p>
         Additional information is available from a retrospective multicenter comparator study of 427 patients with advanced pancreatic cancer previously treated with FOLFIRINOX and then received
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">
          nabpaclitaxel
         </a>
         (n = 219) or gemcitabine alone (n = 208) at the discretion of their clinician [
         <a href="#rid65">
          65
         </a>
         ]. Despite imbalances in the groups that might have favored better outcomes with gemcitabine alone (eg, the group receiving combined therapy had more patients presenting with metastatic disease, more than two metastatic sites, and more peritoneal metastases) combination therapy was associated with a better disease control rate (56 versus 32 percent), modestly better median PFS (3.5 versus 2.3 months), and longer overall survival (7.1 versus 4.7 months). These benefits came at the cost of significantly more treatment-related toxicity (grade ≥3 in 44 versus 29 percent), especially hematologic and neuropathy. These data are obviously limited by their retrospective nature.
        </p>
        <p class="headingAnchor" id="H2825304791">
         <span class="h3">
          Patients with an elevated bilirubin level despite stenting
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients initially treated with FOLFOX because of an elevated total bilirubin level who continue to have an elevated serum bilirubin level, second-line therapy should be undertaken only cautiously as
         <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">
          nanoliposomal irinotecan
         </a>
         ,
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         , and
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         have increased rates of toxicity at standard doses.
        </p>
        <p class="headingAnchor" id="H1462072933">
         <span class="h2">
          Acinar cell cancers
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no established second-line approach to systemic chemotherapy after failure of initial therapy with an oxaliplatin-based regimen such as FOLFOX or FOLFIRINOX. (See
         <a class="medical medical_review" href="/z/d/html/2475.html" rel="external">
          "Initial systemic chemotherapy for metastatic exocrine pancreatic cancer"
         </a>
         .)
        </p>
        <p>
         Options that have been reported as active in case reports or small series include a gemcitabine-based regimen such as GEMOX [
         <a href="#rid66">
          66-68
         </a>
         ],
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         [
         <a href="#rid68">
          68
         </a>
         ] or gemcitabine plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         and
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         [
         <a href="#rid68">
          68
         </a>
         ], S-1 [
         <a href="#rid69">
          69
         </a>
         ] (where available), and an irinotecan-based regimen such as FOLFIRI [
         <a href="#rid70">
          70
         </a>
         ], or cisplatin plus
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         Germline testing might reveal mutations in
         <em>
          BRCA2
         </em>
         for which a PARP inhibitor might be beneficial [
         <a href="#rid71">
          71
         </a>
         ], but the frequency with which germline mutations in DNA damage repair pathways or other potentially actionable genetic alterations are found in acinar cell pancreatic carcinomas is unknown [
         <a href="#rid72">
          72,73
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4251601795">
         <span class="h2">
          Response assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with initial systemic chemotherapy, response assessment during treatment typically relies on periodic cross-sectional radiographic imaging with computed tomography (CT) or magnetic resonance imaging (MRI) (typically every two to three months after treatment initiation) [
         <a href="#rid3">
          3
         </a>
         ]. If they were initially elevated, serum levels of the tumor marker carbohydrate antigen 19-9 (CA 19-9) may be measured at the start of treatment and then every one to three months during therapy. Suspected disease progression based on rising CA 19-9 levels should be confirmed radiographically. (See
         <a class="medical medical_review" href="/z/d/html/2475.html" rel="external">
          "Initial systemic chemotherapy for metastatic exocrine pancreatic cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2438945070">
         <span class="h1">
          ECOG PS 2 OR A COMORBIDITY PROFILE THAT PRECLUDES AGGRESSIVE THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with a borderline Eastern Cooperative Oncology Group (ECOG) performance status (PS) or comorbidity profile that precludes aggressive combination chemotherapy, options for those who wish to pursue cancer-directed therapy include
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         monotherapy or a fluoropyrimidine or taxane monotherapy. The addition of
         <a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">
          nabpaclitaxel
         </a>
         to gemcitabine or
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         to
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         may be offered in this setting, with proactive dose and schedule adjustments to minimize toxicities [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4114606830">
         <span class="h1">
          ECOG PS 3 OR POORLY CONTROLLED COMORBIDITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regardless of histology or breast cancer-associated gene/partner and localizer of
         <em>
          BRCA2
         </em>
         (
         <em>
          BRCA
         </em>
         /
         <em>
          PALB2
         </em>
         ) mutation status, patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥3 or poorly controlled comorbid conditions should only be offered systemic chemotherapy on an individualized, case-by-case basis; supportive care should be emphasized [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H808441193">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111947.html" rel="external">
          "Society guideline links: Pancreatic cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2128802888">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/15493.html" rel="external">
          "Patient education: Pancreatic cancer (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/854.html" rel="external">
          "Patient education: Pancreatic cancer (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2543784142">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         All patients with metastatic pancreatic cancer should be offered aggressive treatment of pain and other symptoms related to the cancer. Early initiation of palliative care services improves clinical and quality-of-care outcomes and may prolong survival. (See
         <a class="local">
          'General principles'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The decision to pursue second-line chemotherapy should be individualized and based on the patient's goals and preferences, and clinical prognostic characteristics such as those delineated in a prognostic
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.umqvc.org%2Fen%2Ftool%2Fproscap.html&amp;token=Yrx3yi7b83pql7MZushMAjWJ0xE34gWDcNZdK5HYE%2Fhul8dxFC9EorBRh%2BRevXxc7P0LssnkkUUqEpNnAPcFLA%3D%3D&amp;TOPIC_ID=127094" target="_blank">
          nomogram
         </a>
         . (See
         <a class="local">
          'Second-line therapy versus supportive care alone and patient selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Next generation sequencing should be routinely obtained given the emerging roles of therapies that target specific populations such as those with
         <em>
          KRAS
         </em>
         <em>
          G12C
         </em>
         mutations, TRK fusions, and deficient mismatch repair. (See
         <a class="local">
          'Molecularly-targeted therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Enrollment in clinical trials is preferred, if available. If protocol treatment is not available or participation is not feasible, we base our treatment choice on clinical characteristics, including performance status (PS) and comorbidity, the results of genomic testing and next generation sequencing of tumor tissue, histology, the first-line regimen, and patient preference.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with adequate performance status and comorbidity
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Homologous recombination repair deficiency
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with a germline mutation in
         <em>
          BRCA
         </em>
         or
         <em>
          PALB2
         </em>
         who received maintenance therapy with a poly(ADP-ribose) polymerase (PARP) inhibitor after at least 16 weeks of a platinum containing regimen for first-line therapy, options at the time of disease progression include retreatment with the initial platinum-based regimen or administration of a different platinum-containing regimen than what was administered first-line (eg, FOLFOX for a patient who previously received
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         , or vice versa). (See
         <a class="local">
          'BRCA or PALB2 mutation carriers and other homologous recombination repair deficiency alterations'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2475.html" rel="external">
          "Initial systemic chemotherapy for metastatic exocrine pancreatic cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with any germline or somatic homologous recombination repair (HRR) deficiency-associated pathogenic variant who did not undergo maintenance therapy with
         <a class="drug drug_general" data-topicid="98761" href="/z/d/drug information/98761.html" rel="external">
          olaparib
         </a>
         after first-line platinum-containing chemotherapy, a PARP inhibitor could be used off-label for second-line therapy, especially for those with a pathogenic or likely pathogenic variant in
         <em>
          BRCA 1
         </em>
         or
         <em>
          2
         </em>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For patients who did not receive initial platinum-based chemotherapy, we suggest a platinum-based chemotherapy regimen (eg,
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         , FOLFOX  (
         <a class="graphic graphic_table graphicRef50132" href="/z/d/graphic/50132.html" rel="external">
          table 2
         </a>
         ), FOLFIRINOX  (
         <a class="graphic graphic_table graphicRef79571" href="/z/d/graphic/79571.html" rel="external">
          table 3
         </a>
         ), or modified FOLFIRINOX  (
         <a class="graphic graphic_table graphicRef109546" href="/z/d/graphic/109546.html" rel="external">
          table 4
         </a>
         )) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Deficient mismatch repair or high tumor mutational burden
         </strong>
         – For second-line therapy of individuals with deficient mismatch repair or a high tumor mutational burden, we suggest
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         monotherapy  (
         <a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">
          table 10
         </a>
         ) rather than cytotoxic chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Deficient mismatch repair or high tumor mutational burden'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          TRK fusion-positive cancers
         </strong>
         – For patients with tropomyosin receptor kinase (TRK) fusion-positive cancers, we suggest a TRK inhibitor (
         <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">
          larotrectinib
         </a>
         or
         <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">
          entrectinib
         </a>
         ) rather than cytotoxic chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'TRK fusion-positive cancers'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           RAS
          </em>
         </strong>
         <strong>
         </strong>
         <strong>
          <em>
           G12C
          </em>
         </strong>
         <strong>
          -mutated tumors
         </strong>
         – For patients with a
         <em>
          RAS
         </em>
         <em>
          G12C
         </em>
         mutation who have progressed on initial chemotherapy, we suggest
         <a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">
          sotorasib
         </a>
         rather than cytotoxic chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'RAS G12C-mutated tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Non-targeted therapies for adenocarcinoma
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For individuals previously treated with first-line FOLFIRINOX who retain an ECOG PS of 0 to 1  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 1
         </a>
         ), normal biliary function, continued favorable comorbidity  (
         <a class="graphic graphic_table graphicRef118194" href="/z/d/graphic/118194.html" rel="external">
          table 6
         </a>
         ), a preference and support system for aggressive medical therapy, we suggest
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="10159" href="/z/d/drug information/10159.html" rel="external">
          nabpaclitaxel
         </a>
         (
         <a class="graphic graphic_table graphicRef89668" href="/z/d/graphic/89668.html" rel="external">
          table 7
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For others, gemcitabine monotherapy  (
         <a class="graphic graphic_table graphicRef60330" href="/z/d/graphic/60330.html" rel="external">
          table 8
         </a>
         ), gemcitabine plus
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         (
         <a class="graphic graphic_table graphicRef103038" href="/z/d/graphic/103038.html" rel="external">
          table 9
         </a>
         ), or a fluoropyrimidine alone are all reasonable options. (See
         <a class="local">
          'After first-line FOLFIRINOX'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients treated initially with a gemcitabine-containing regimen who retain an ECOG PS of 0 to 1  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 1
         </a>
         ), a favorable comorbidity profile  (
         <a class="graphic graphic_table graphicRef118194" href="/z/d/graphic/118194.html" rel="external">
          table 6
         </a>
         ), a preference and support system for aggressive medical therapy, options include FOLFIRI,
         <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">
          liposomal irinotecan
         </a>
         in combination with FU (as long as liver function is adequate)  (
         <a class="graphic graphic_table graphicRef109026" href="/z/d/graphic/109026.html" rel="external">
          table 11
         </a>
         ), or FU plus
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         (
         <a class="graphic graphic_table graphicRef50132" href="/z/d/graphic/50132.html" rel="external">
          table 2
         </a>
         ). FOLFIRINOX  (
         <a class="graphic graphic_table graphicRef79571" href="/z/d/graphic/79571.html" rel="external">
          table 3
         </a>
         ) or modified FOLFIRINOX  (
         <a class="graphic graphic_table graphicRef109546" href="/z/d/graphic/109546.html" rel="external">
          table 4
         </a>
         ) may be offered to patients with limited neuropathy and an excellent PS. (See
         <a class="local">
          'After first-line gemcitabine'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">
          "Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Irinotecan'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/85690.html" rel="external">
          "Treatment protocols for pancreatic cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients previously treated with a gemcitabine-containing regimen who have an ECOG PS of 2 but relatively favorable comorbidity  (
         <a class="graphic graphic_table graphicRef118194" href="/z/d/graphic/118194.html" rel="external">
          table 6
         </a>
         ), we suggest monotherapy with a fluoropyrimidine, S-1 (where available) or a taxane (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'ECOG PS 2 or a comorbidity profile that precludes aggressive therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients initially treated with FOLFOX who have a persistently elevated serum bilirubin, second-line therapy should be undertaken only cautiously;
         <a class="drug drug_general" data-topicid="104962" href="/z/d/drug information/104962.html" rel="external">
          liposomal irinotecan
         </a>
         (
         <a class="graphic graphic_table graphicRef109026" href="/z/d/graphic/109026.html" rel="external">
          table 11
         </a>
         ),
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         (
         <a class="graphic graphic_table graphicRef76300" href="/z/d/graphic/76300.html" rel="external">
          table 12
         </a>
         ),
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         alone  (
         <a class="graphic graphic_table graphicRef60330" href="/z/d/graphic/60330.html" rel="external">
          table 8
         </a>
         ), and
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         are all more toxic at standard doses. (See
         <a class="local">
          'Patients with an elevated bilirubin level despite stenting'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acinar cell carcinoma
         </strong>
         – There is no established second-line approach to systemic chemotherapy after failure of initial therapy with an oxaliplatin-based regimen such as FOLFOX or FOLFIRINOX. Options include GEMOX  (
         <a class="graphic graphic_table graphicRef90451" href="/z/d/graphic/90451.html" rel="external">
          table 13
         </a>
         ),
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         (
         <a class="graphic graphic_table graphicRef89633" href="/z/d/graphic/89633.html" rel="external">
          table 14
         </a>
         ), gemcitabine plus
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         and
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         , S-1 (where available), or an irinotecan-based regimen such as FOLFIRI, or cisplatin plus
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ECOG performance status 3 or poor comorbidity
         </strong>
         – Patients with an ECOG PS ≥3 or poorly controlled comorbid conditions should only be offered systemic chemotherapy on an individualized, case-by-case basis; supportive care should be emphasized. (See
         <a class="local">
          'ECOG PS 3 or poorly controlled comorbidity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H149796837">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges David P Ryan, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011; 47:1676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vienot A, Beinse G, Louvet C, et al. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. J Natl Cancer Inst 2017; 109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic Pancreatic Cancer: ASCO Guideline Update. J Clin Oncol 2020; 38:3217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park W, Chen J, Chou JF, et al. Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. Clin Cancer Res 2020; 26:3239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang H, Mao C, Li N, et al. A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation. Medicine (Baltimore) 2019; 98:e17443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borazanci E, Korn R, Liang WS, et al. An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor. Oncologist 2020; 25:e60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahn ER, Garrett-Mayer E, Halabi S, et al. Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. J Clin Oncol 2020; 38S:ASCO #4637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Javle M, Shacham-Shmueli E, Xiao L, et al. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials. JAMA Oncol 2021; 7:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372:2509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 2020; 38:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Middha S, Zhang L, Nafa K, et al. Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. JCO Precis Oncol 2017; 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Reilly EM, Oh DY, Dhani N, et al. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol 2019; 5:1431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Latham A, Srinivasan P, Kemel Y, et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol 2019; 37:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ott PA, Bang YJ, Piha-Paul SA, et al. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J Clin Oncol 2019; 37:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pishvaian MJ, Blais EM, Brody JR, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol 2020; 21:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al Baghdadi T, Halabi S, Garrett-Mayer E, et al. Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol 2019; 3:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol 2022; 23:1261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kato S, Subbiah V, Marchlik E, et al. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clin Cancer Res 2017; 23:1988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okamura R, Boichard A, Kato S, et al. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precis Oncol 2018; 2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon JP, Linkov I, Rosado A, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol 2020; 33:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Reilly EM, Hechtman JF. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion. Ann Oncol 2019; 30:viii36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020; 21:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo J. KRAS mutation in pancreatic cancer. Semin Oncol 2021; 48:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hosein AN, Dougan SK, Aguirre AJ, Maitra A. Translational advances in pancreatic ductal adenocarcinoma therapy. Nat Cancer 2022; 3:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hong DS, Fakih MG, Strickler JH, et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med 2020; 383:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strickler JH, Satake H, George TJ, et al. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med 2023; 388:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sohal DPS, Kennedy EB, Khorana A, et al. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2018; 36:2545.
          </a>
         </li>
         <li class="breakAll">
          NCCN Guidelines &amp; Clinical Resources. Available at: https://www.nccn.org/professionals/physician_gls/ (Accessed on May 24, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang TC, Shiah HS, Yang CH, et al. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother Pharmacol 2015; 75:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016; 387:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gebbia V, Maiello E, Giuliani F, et al. Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol 2010; 33:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaniboni A, Aitini E, Barni S, et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol 2012; 69:1641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pointet AL, Tougeron D, Pernot S, et al. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study. Clin Res Hepatol Gastroenterol 2020; 44:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ioka T, Komatsu Y, Mizuno N, et al. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer 2017; 116:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berk V, Ozdemir N, Ozkan M, et al. XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 2012; 59:2635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaanan A, Trouilloud I, Markoutsaki T, et al. FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. BMC Cancer 2014; 14:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee K, Bang K, Yoo C, et al. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Cancer Res Treat 2020; 52:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiong HQ, Varadhachary GR, Blais JC, et al. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008; 113:2046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohkawa S, Okusaka T, Isayama H, et al. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer 2015; 112:1428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demols A, Peeters M, Polus M, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006; 94:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fortune BE, Li X, Kosuri KV, et al. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study. Oncology 2009; 76:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cantore M, Rabbi C, Fiorentini G, et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 2004; 67:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoo C, Hwang JY, Kim JE, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009; 101:1658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ettrich TJ, von Wichert G, Gress TM, et al. DOCOX: A phase II trial with docetaxel and oxaliplatin as a second-line systemic therapy for patients with advanced and/or metastatic adenocarcinoma of the pancreas. J Clin Oncol 2013; 31S:ASCO #4034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsavaris N, Kosmas C, Skopelitis H, et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest New Drugs 2005; 23:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gebbia V, Maiello E, Giuliani F, et al. Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. Ann Oncol 2007; 18 Suppl 6:vi124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014; 32:2423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill S, Ko YJ, Cripps C, et al. PANCREOX: A Randomized Phase III Study of 5-Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. J Clin Oncol 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Assaf E, Verlinde-Carvalho M, Delbaldo C, et al. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology 2011; 80:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sonbol MB, Firwana B, Wang Z, et al. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Cancer 2017; 123:4680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sudo K, Yamaguchi T, Nakamura K, et al. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol 2011; 67:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morizane C, Okusaka T, Ueno H, et al. Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients. Cancer Chemother Pharmacol 2012; 69:957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulke MH, Blaszkowsky LS, Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007; 25:4787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ulrich-Pur H, Raderer M, Verena Kornek G, et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003; 88:1180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reni M, Pasetto L, Aprile G, et al. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 2006; 94:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maeda S, Motoi F, Onogawa T, et al. Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Int J Clin Oncol 2011; 16:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hosein PJ, de Lima Lopes G Jr, Pastorini VH, et al. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol 2013; 36:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Portal A, Pernot S, Tougeron D, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer 2015; 113:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mita N, Iwashita T, Uemura S, et al. Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure. J Clin Med 2019; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           da Rocha Lino A, Abrahão CM, Brandão RM, et al. Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis. J Gastrointest Oncol 2015; 6:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viaud J, Brac C, Artru P, et al. Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study. Dig Liver Dis 2017; 49:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilabert M, Chanez B, Rho YS, et al. Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. Medicine (Baltimore) 2017; 96:e6544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarabi M, Mais L, Oussaid N, et al. Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. Oncol Lett 2017; 13:4917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaibet S, Hautefeuille V, Auclin E, et al. Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. Br J Cancer 2022; 126:1394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Béchade D, Desjardin M, Salmon E, et al. Pancreatic Acinar Cell Carcinoma. Case Rep Gastroenterol 2016; 10:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunetti O, Aprile G, Marchetti P, et al. Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis. Pancreas 2018; 47:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowery MA, Klimstra DS, Shia J, et al. Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy. Oncologist 2011; 16:1714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sumiyoshi T, Shima Y, Okabayashi T, et al. Long-term survival following pancreatectomy and s-1 chemotherapy for pancreatic acinar cell carcinoma with peritoneal dissemination: a case report and literature review. Medicine (Baltimore) 2015; 94:e378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holen KD, Klimstra DS, Hummer A, et al. Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol 2002; 20:4673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li M, Mou Y, Hou S, et al. Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report. Medicine (Baltimore) 2018; 97:e13113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiao Y, Yonescu R, Offerhaus GJ, et al. Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. J Pathol 2014; 232:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chmielecki J, Hutchinson KE, Frampton GM, et al. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. Cancer Discov 2014; 4:1398.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 127094 Version 19.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21565490" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28383673" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32755482" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Metastatic Pancreatic Cancer: ASCO Guideline Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32444418" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31577767" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31391296" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33662100" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26028255" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28596308" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31682550" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30211344" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31318392" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30376427" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30557521" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32135080" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35100714" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36108661" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27683183" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30637364" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31375766" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31605106" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31838007" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33676749" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : KRAS mutation in pancreatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35352061" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Translational advances in pancreatic ductal adenocarcinoma therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32955176" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36546651" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29791286" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29791286" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25577133" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26615328" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20142727" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22576338" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31607641" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28081543" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22534542" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24929865" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31291709" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18756532" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25880004" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16434988" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19307739" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15539911" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19826418" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : DOCOX: A phase II trial with docetaxel and oxaliplatin as a second-line systemic therapy for patients with advanced and/or metastatic adenocarcinoma of the pancreas
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16012797" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17591805" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24982456" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27621395" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : PANCREOX: A Randomized Phase III Study of 5-Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21778770" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28817187" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20352216" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22120961" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17947726" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12698181" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16508631" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21455624" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22307213" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26372701" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31146420" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26487945" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28256401" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28422841" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28599496" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35094032" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27403122" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Pancreatic Acinar Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29771769" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22042785" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25569665" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Long-term survival following pancreatectomy and s-1 chemotherapy for pancreatic acinar cell carcinoma with peritoneal dissemination: a case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12488412" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30407325" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24293293" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Whole-exome sequencing of pancreatic neoplasms with acinar differentiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25266736" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
